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Abstract:
Parkinson’s disease (PD) is a common neurodegenerative disorder, affecting up to 10 million people worldwide
according to the Parkinson’s Disease Foundation. Epidemiological and genetic studies show a preponderance
of idiopathic cases and a subset linked to genetic polymorphisms of a familial nature. Traditional Chinese
medicine and Ayurveda recognized and treated the illness that Western Medicine terms PD millennia ago, and
descriptions of Parkinson’s symptomatology by Europeans date back 2000 years to the ancient Greek physician
Galen. However, the Western nosological classification now referred to in English as “Parkinson’s disease” and
the description of symptoms that define it, are accredited to British physician James Parkinson, who in 1817
authored The Shaking Palsy. Later in the nineteenth century, French neurologist Jean-Martin Charcot re-labeled
paralysis agitans “Parkinson’s disease” and over a century of scientific research ensued. This review discusses
European, North American, and Asian contributions to the understanding and treatment of PD from ancient
times through the twentieth century.
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative disorder, affecting up to 10 million people world-
wide according to the Parkinson’s Disease Foundation. The diagnosis of PD is based on the presence of clinical
symptoms that have been refined over centuries and characterized across various cultures. At present, the In-
ternational Parkinson and Movement Disorder Society clinical diagnostic criteria focus on motor abnormalities
that include bradykinesia (slowness or poverty of movement) plus resting tremor or muscular rigidity [1]. In
this article I delve broadly and deeply into the historical development of the Parkinson’s diagnosis, and the
Western and Eastern perspectives that have contributed to the understanding of PD. This article will also focus
on treatment of PD across cultures and millennia and will discuss historic breakthroughs in the neurosciences
that have improved and extended quality of life in PD patients.
James Parkinson
James Parkinson (1755–1824) was a physician practicing in Hoxton Square in the Shoreditch district of Lon-
don in the late seventeenth, early eighteenth centuries [2]. Parkinson was an eclectic man, with interests that
spanned medicine, politics, geology, and paleontology. In 1817, Parkinson published his now famous mono-
graph entitled An Essay on the Shaking Palsy [[3](see Figure 1)].Parkinson referred to the malady as paralysis
agitans (shaking palsy). While various accounts of symptoms that resemble that which we now term PD had
been given before Parkinson’s famous essay, he was one of the first to shine a spotlight on the symptoms of
resting tremor, postural instability, and slowness of movement as characteristic of a single disease process.
Parkinson based his postulate- that these symptoms form a distinct disease- on a series of six cases, some of
which he merely observed in the street. In Parkinson’s essay, he described the symptoms of paralysis agitans in
detail and distinguished them from other maladies. For example, he noted that “resting” rather than what is
now termed “intention” tremor, is a hallmark of the disease. The disease that Parkinson described and that is
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now named after him is idiopathic PD – as opposed to postencephalitic, post-traumatic, or PD secondary to
manganese exposure [4]. Parkinson’s astute observations are relevant to this day. In a biographical essay pub-
lished in 1955, William McMenemey stated that Parkinson’s “account of the disease is unsurpassed in the annals
of medicine.” So important is Parkinson’s contribution to the understanding of this disease that his birthday
– April 11th, was declared World Parkinson’s Day in 1997 and organizations around the world use this day to
raise awareness of the disease and to raise funds to support research, clinical, and educational efforts.
Figure 1: Cover of An Essay on the Shaking Palsy, published as a monograph in 1817 by Sherwood, Neely, and Jones, Lon-
don. Source: Wellcome Library London.
Wellcome Collection. Photograph available under public license at this URL.
Parkinson’s essay also provides broader insights into the history of Western medicine. In particular, Parkin-
son notes that the “shaking palsy” as he described it, “has not yet obtained a place in the classification of
nosologists” (Parkinson, 1917, p. ii). Thus while he credits others including Galen (129–199), Sylvius de la Boë
(1614–1672), Boissier de Sauvages de la Croix (1706–1767), and Gaubius (1705–1780) as having described some
of the individual symptoms that constitute the disease, he himself classifies the symptoms, their timing and
progression, as a single pathological process worthy of recognition in medical taxonomy. Parkinson went so
far as to attempt to identify causality: “slow morbid change in the structure of the medulla, or its investing mem-
branes, or theca, occasioned by simple inflammation, or rheumatic or scrophulous affection” (Parkinson, 1817,
p. 52), but it is the recognition of the symptom cluster and the disease progression that proved to be prescient
and that earned him lasting recognition in the annals of medicine. In 1884, some 60 years after the publica-
tion of his essay, French neurologist Jean-Martin Charcot (1825–1893) added rigidity to the symptomatology of
paralysis agitans and renamed it “maladie de Parkinson” or PD [4, 5].
As originally noted by Parkinson, PD increases in frequency with advancing age and is most likely to develop
in individuals over the age of 50. The average age of onset is about 60 and there is evidence that it continues
to increase in prevalence until the ninth decade when the incidence begins to decline. In Parkinson’s time, life
expectancy was shorter than it is in many countries presently, and the population of aging individuals was
considerably smaller. Hence the disease afflicted fewer people. Furthermore, as Parkinson pointed out, the dis-
ease is of long duration and years passes before the affliction is severe enough to cause death. However, in the
twenty-first century, individual life expectancy in many counties is 80 years and beyond and the population of
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older individuals is increasing dramatically. In this context, the diagnosis of an age-associated slowly progres-
sive neurodegenerative disease in ones fifties or sixties is very likely to impact quality of life and shorten the
lifespan.
One important omission in Parkinson’s description of the “shaking palsy” is dysfunction in cognition and
emotion that we now recognize may accompany the disease process. This is apparent in the following definition
of the disease given in “An Essay on the Shaking Palsy” and quoted by McMenemey [2]:
Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when
supported, with a propensity to bend the trunk forwards and to pass from a walking to a running pace:
the senses and the intellects being uninjured (p. 123)
The focus on PD as primarily motoric in nature has dominated the approach to research and treatment for cen-
turies. In the last few decades however, it is increasingly recognized that neuropsychiatric symptoms, including
depression, anxiety, and cognitive decline, contribute to disability and loss of quality of life [6].
In sum, James Parkinson formalized the disease as distinct from others, and this was reinforced by Charcot
and subsequent generations of neurologists who call paralysis agitans or the shaking palsy “Parkinson’s disease.”
However, the disease been documented world-wide for millennia. What understanding of the disease and its
symptoms existed in Europe and on other continents prior to Parkinson?
History of PD prior to James Parkinson
Europe
Historical documents indicate that PD was recognized prior to the publication of James Parkinson’s essay. As
described previously, Parkinson himself referred to several of these accounts and integrated them into his for-
mulation of paralysis agitans. One early account of importance that Parkinson did not reference was that of
Hungarian physician Ferenc Pápai Páriz (1649–1716). According to an article by Daniel Bereczki [7], Páriz de-
scribed all four signs of PD: tremor, hypokinesia, rigidity, and instability of gait- in a monograph published in
Hungarian in 1690 entitled Pax corporis. Symptoms of what we now refer to as PD as quoted by Bereczki [7] were
described in the third chapter of this book, “On tremulousness and paresis of the hand, leg, tongue, and other
parts” (p. 291). Páriz also discussed the progressive nature of the disease and, in contrast to James Parkinson
who located the disease in the spinal cord, suggested its locus in the “head” as emanating from the “substance
of the brain” (Bereczki, 2010, p. 292). Páriz’ account appears to be the most thorough description that was pub-
lished prior to the “An Essay on the Shaking Palsy” by James Parkinson. To some extent, Páriz’ depiction may
have been more accurate. However, his text was not published in Latin and therefore was not widely read in
Western Europe. Moreover, his chapter on tremulousness was only eight pages long, much shorter than Parkin-
son’s monograph written more than a century later. It is only recently that Páriz’ findings have come to light
[7].
In the fifteenth century, Leonardo Da Vinci’s writing described a condition resembling PD. Stern [8] provides
a quote: “for you will see paralytics and those who are shivering and benumbed by cold move their trembling
parts, such as their heads or hands without permission of the soul” (p. 12). Stern suggests that it is likely that
DaVinci had seen the shaking palsy between 1489 and 1506, based on this observation having been noted on
an anatomical drawing in the collection of the Queen at Windsor Castle. Prior to this, Greek physician Galen,
writing between CE 129 and 199, described what we now term “festination” and other symptoms typical of
PD [8]. As quoted by Stern [8], Galen describes a gait disorder as “a kind of paralysis which prevents people
walking by mixing up the sides, exchanging left for right and right for left, failing to lift the foot and pulling it
back instead, like those who walk up a steep incline” (p. 12). Galen may have also been the first to distinguish
resting and action tremor, the former being characteristic of PD.
China
Traditional Chinese medicine (TCM) has evolved over several thousand years and is rooted in Taoism. It in-
cludes the use of botanical and medicinal preparations as well as practices such as acupuncture, tai chi, qi gong,
and therapeutic massage to treat a variety of afflictions. Descriptions of a Parkinson’s-like illness first appear in
the Yellow Emperor’s Internal Classic around 425–221 B.C. Volume 22 of the 24 volume classic describes symp-
toms of tremor and stiffness, crouching of the head and staring of the eyes, bending of the trunk with drooped
shoulders, and tremor while walking [9]. Later, in AD 220–228 during Dynasty 6, a description of Parkinson-like
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festinating gate is given in the book Hua’s Zhong Zang Classic. During the Jin dynasty, TCM expert Zhang Zihe
(AD 1151-1231) gave a detailed account in his book Rumenshiqin of “wind shaking” in a man whose symptoms
include tremor, stiffness, inability to perform motor activities, and loss of dexterity in addition to depressed af-
fect. He also described a treatment termed Fangfeng Tongsheng Powder that included several Chinese botanicals
[9, 10]. During the sixteenth and seventeenth centuries, several practitioners of TCM described the symptoms of
PD in considerable detail. Sun Yikui (1522–1619) of the Ming Dynasty named the disease Chanzheng or “tremor
syndrome in the elderly [10].” He developed a treatment to eliminate liver pathogens termed CuiganWan that
consisted of a variety of plant-based derivatives [10]. Pharmacologic studies of these compounds, still in use
today by practitioners of TCM, show that they have anticholinergic, antioxidant, and free radical scavenging
effects [9]. The herb gastrodia, used in TCM preparations, increases dopamine levels in an animal model and
may possess neuroprotective effects [9].
In addition to herbal medicine, TCM practices such as acupuncture and tai chi have proven beneficial in PD.
The application of acupuncture to alleviate Parkinson-like symptoms dates back centuries. An entry recorded
by Zhang Zhongjing (152–219 AD) in the “Treatise on Cold Damage and Miscellaneous Diseases” recommends
acupuncture for a disease he named Fujue, a PD-like syndrome [10]. Acupuncture points are selected in accor-
dance with TCM theory. In a recent meta-analysis based on 19 Chinese and Korean clinical trials, acupuncture
was found to be effective in improving PD motor function, particularly when used in conjunction with conven-
tional pharmaceutical treatment [11]. Based on preclinical studies in mice, the authors suggest that acupuncture
may prevent cell death in the pars compacta region of the substantia nigra. They recommend targeting specific
acupuncture points to achieve this effect. Studies in mice also indicate that acupuncture promotes clearance of
alpha synuclein, a protein that aggregates in PD brains [12].
Like acupuncture, the ancient Chinese martial art, tai chi, is also used to alleviate Parkinsonian symptoms.
Tai Chi combines slow and graceful body movements and deep breathing. It has been particularly well-studied
in PD recently as a practice that improves postural stability and balance and reduces the incidence of falls
[13, 14]. In TCM, yin and yang must be balanced to support energy flow (qi) and health. When these forces
are not in balance, qi stagnation can occur. Acupuncture and Tai Chi may exert positive effects on PD patients
by harmonizing the yin and yang aspects of qi. In scientific medicine, these concepts may be understood as
analogous to metabolism, immunity, and homeostatis [15]. More specifically, studies designed to uncover the
neurobiological basis of TCM “mind-body” practices suggest that they may exert their healing effects in PD
by reducing inflammation and increasing blood flow, electrical signaling, and neurotransmitter bioavailability
[16–18]. Recently a group of Chinese neurologists published consensus guidelines for the integrative treatment
of PD in China [19]. They recommended specific and/or personalized TCM treatments (depending upon the
expertise of the practitioner), in conjunction with Western pharmaceutical and surgical interventions.
India
Perhaps the earliest written description of an illness that resembles what Western medicine terms PD is found
in ancient Ayurvedic texts. Ayurveda, translated as “the science of life,” is a medical system practiced in India
and developed by the Vedic culture over 5000 years ago [20]. The major text, Charaka Samhita, dates to about
2400 BP. Descriptions written in Sanskrit of a disease that includes tremor, drooling, difficulty with movement,
and depression appear in this ancient Ayurvedic text and in subsequent texts written in between the fifth and
twelfth centuries [21, 22]. This disease was named kampavata in fifteenth century Ayurvedic literature [22]. Vata
is one of three doshas or bodily humors that make up one’s constitution. Vata governs movements and sensa-
tions. Kampa means tremor. In Ayurvedic medicine, the disease was treated with a preparation termed Masa-
baladi Pacana that was derived from Mucuna pruriens [21, 23]. This plant is a member of the Leguminosae family
which is indigenous to India. It contains 4%–6% L-3, 4-dihydroxyphenylalanine or levodopa (L-dopa) and may
also have dopamine agonist activity [24, 25]. Research in an animal model suggests that Mucuna pruriens may
be more effective than synthetic L-Dopa in treating Parkinson’s symptoms [26]. A small clinical trial in Parkin-
son patients conducted in 2004 showed that Mucuna pruriens powder produced a more rapid onset and longer
duration of “on” time without increases in dyskinesias when compared with standard L-dopa/carbidopa [27].
Aruyvedic physicians also gave additional neuroactive botanicals in conjunction with Mucuna pruriens, includ-
ing ashwagandha (Withania somnifera), a botanical known to reduce anxiety, and bala (Sida cordifolia), a medic-
inal plant that contains ephedrine, a norepinephrine agonist. These herbs are currently available as dietary
supplements and can be purchased on the internet. Thus millennia prior to Nobel Laureate Arvid Carlsson’s
discovery in the 1950s that dopamine is a neurotransmitter involved in the control of movement, or Birkmayer
and Hornykiewicz’ 1961 trial demonstrating “miraculous” results using L-Dopa as a therapeutic agent in PD
[28], Ayurvedic practitioners were giving kampavata patients L-dopa.
Another tradition rooted in the Vedic philosophy of ancient India that has benefitted PD patients is yoga.
Yoga originated as a spiritual practice that combines bodily poses with meditation and breathing. The West
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has adopted yoga as a “mind-body” modality and recent studies suggest that it may improve motor function
and quality of life in PD patients [29, 30]. From a scientific perspective, yoga is not as well studied in PD as
acupuncture and tai chi. However, its mechanisms of action may be similar. In particular, evidence suggests that
yoga has neuroprotective effects such as preserving gray matter volume, increasing regional brain functional
connectivity, and reducing inflammation [31]. Yoga represents another ancient Eastern practice that is used in
conjunction with medicinal treatments to benefit PD patients.
Nineteenth century European developments in the understanding and treatment of
PD
Following the publication of “An Essay on the Shaking Palsy”, additional accounts of PD appeared in the
literature. Wilhelm von Humboldt (1767–1835), German scholar, statesman, and founder of the Berlin Univer-
sity, gave a lay account of his personal experience with PD in a lengthy correspondence with friend Charlotte
Diede (1769–1846). In these letters, published after the Diede’s death, von Humboldt described with excep-
tional precision the symptoms of PD [32]. These included trembling, difficulty with fine motor movements,
micrographia, and slowness of movement. He attributed these symptoms to advancing age and the death of
his wife. Von Humboldt’s brother, renowned naturalist Alexander von Humboldt, wrote on the occasion of
Wilhelm’s death, that his brother had a curved posture, tremor and that his death was caused by pneumo-
nia. One year prior, von Humboldt’s daughters reported that their father looked very thin, exhibited slowness
of movement, tremor, curved posture and what we would now term “aprosodia” or monotone speech. Von
Humboldt’s curved posture is shown in a statuette of him by Friedrich Drake dated 1834, one year prior to von
Humboldt’s death [32].
Jean-Martin Charcot (1825–1893; Figure 2), widely considered the “father” of neurology, made notable con-
tributions to our understanding of PD.
Figure 2: Jean Marie Charcot (1825–1893); Source: Wellcome Library London.
Wellcome Collection. Photograph available under public licence at this URL.
As described previously, Charcot renamed paralysis agitans “maladie de Parkinson.” As a neurologist and
academician at the famous Salpêtrière Hospital in Paris, France, Charcot established the first neurology clinic
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in Europe and saw hundreds of patients over the three plus decades he practiced there. Charcot had diverse
interests, spanning psychiatry and neurology. He conducted extensive studies of tremor and contrasted typical
and atypical variants of PD. The atypical presentations Charcot described would likely be termed Parkinson-
plus syndromes currently [(corticobasal degeneration, progressive supranuclear palsy, and multiple system
atrophy)[33]]. Charcot also developed treatments for PD. These treatments largely targeted tremor and con-
sisted of preparations that have anticholinergic effects, such as belladonna and hyoscyamine, tropane alkaloids
found in plants belonging to the Solanaceae or nightshade family. He also treated PD patients with ergot alka-
loids. Ergot products are derived from a fungus present in rye. These compounds induce vasoconstriction and
act as dopamine, serotonin, and norepinephrine receptor agonists. Charcot observed that Parkinson patients
obtained some relief from resting tremor after carriage or horseback rides and postulated that the vibration
was responsible for the effect. He designed an electrically powered “shaking chair” that he used in treatment
[33]. Later, his student Gilles de la Tourette developed a shaking helmet that could be more easily transported.
Neither of these treatments gained widespread use.
Another important figure in the history of PD was British neurologist Sir William R. Gowers (1845–1915;
Figure 3). Gowers devoted an entire chapter to paralysis agitans in his famous textbook entitled “Manual of
Diseases of the Nervous System” [34].
Figure 3: Sir William R. Gowers (1845–1915). Source Wellcome Library London.
Wellcome Collection. Sir William Richard Gowers. Photogravure after Maull and Fox. Photograph available under public
license at this URL.
In 1945, Macdonald Critchley stated that Gowers was “probably the greatest clinical neurologist of all time”
[35]. Many of Gowers’ observations remain accurate to this day. For instance, he noted that the disease is more
frequent in men than in women, that it usually begins after age 40 that heredity can be traced in about 15%
of cases, and that it has a chronic and progressive course. He considered various precipitating factors and
described the symptoms of PD in great detail, including the observation that the “facial muscles seem to be
unable to respond to the varying changes of emotion.” He astutely observed that “mental depression” may
accompany the disease and expressed uncertainty as to whether depression is a result of the physical ailment.
This foreshadowed the prevailing view that Parkinsonian depression may stem from abnormalities in neuro-
transmitters as well as fronto-subcortical connections that regulate mood [6]. Gowers also notes that loss of
memory accompanied by delusions is sometimes present in late stages. He describes the disease as involving
the central nervous system, and asks rhetorically whether the motor cortex is the seat of the disease. Very little
information on the neuropathology of PD was known at the time or is presented in Gowers’ text. He describes
treatments for tremor that were in use in Europe, including morphine, hyoscyamin, static and voltaic electricity,
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opium, Indian hemp, and arsenic. Indian hemp is a cannabinoid that was imported from Kolkata to the British
Isles in the nineteenth century and used by Gowers in the treatment of PD. That plus opium combined with
arsenic was his preferred remedy.
Neuropathological discoveries
Identification of the neuropathology of PD commenced in the late nineteenth century when Edouard Brissaud
(1852–1909), a student of Charcot and his successor at the Salpêtrière Hospital in Paris, suggested that the
substantia nigra may be involved in PD based on a prior case report. This idea did not gain traction for decades
while various other theories emerged regarding the pathogenesis of the disease [4].
In 1919 the Russian pathologist Konstantin Tretiakoff (1892–1958) produced a doctoral dissertation
l’Anatomie pathologique du Locus Niger in which he examined the substantia nigra of 54 brains including six
with paralysis agitans. He noted marked loss of pigmented neurons in the substantia nigra associated with PD
in addition to other pathological features including inclusion bodies, which he named “corps de Lewy” after
Friedrich Lewy who had described them 7 years previously [36]. Tretiakoff’s thesis, that lesions in the substan-
tia nigra were pathonomic of PD, was not widely accepted at the time, despite the fact that it may have been
one of the most important neuropathological findings of the twentieth century [36]. In 1925 French Neurolo-
gist Jean Llermitte conceded that all cases of PD studied contained lesions of the substantia nigra as described
by Tretiakoff. Work by Charles Foix and Cecile and Oskar Vogt conducted in the 1920s and 1930s contributed
to current understanding of the role of the basal ganglia and substantia nigra in PD. Two decades later, their
daughter Marthe Vogt, conducted landmark studies of the distribution of epinephrine and norepinephrine in
the brain [37]. In 1938, Rolf Hassler, working in the laboratory of the Vogts’, completed a thorough examina-
tion of the substantia nigra in 9 cases of paralysis agitans and 11 cases of post-encephaletic PD. He concluded
that lesions of the substantia nigra were a hallmark of the disease [38]. This was later confirmed by Bertler
and Rosengren in 1959 who used histofluorescence to demonstrate severe nigrostriatal loss in PD [36]. In 1960,
Ehringer and Hornykiewicz measured dopamine in the autopsied brains of patients with Huntington’s dis-
ease, PD, and other extrapyramidal disorders and found that only the Parkinson brains had severe dopamine
cell loss in the caudate and putamen [39]. Subsequent neuropathological findings include the discovery in 1997
that alpha-synuclein, a presynaptic protein present in brain tissue, is the main component of Lewy Bodies in
idiopathic PD and in dementia with Lewy bodies [40]. PD is currently classified as an alpha-synucleinopathy
together with Lewy Body dementia and multiple system atrophy. Braak et al. [41] suggested that motor and
non-motor symptoms in idiopathic PD are related to a larger pathologic process involving a progressive caudal
to rostral aggregation of alpha-synuclein in select nerve cells, although this is somewhat controversial [42, 43].
Discovery of L-DOPA, dopamine and advances in the treatment of PD
As this review illustrates, practitioners of Ayurveda, TCM, and European neurology were using botanical
preparations to treat Parkinson symptomatology centuries ago. These plant-based medicinals included but
were not limited to gastrodia, Mucuna pruriens, ashwagandha, bala, belladonna, hyoscyamin, and cannabis. Be-
ginning in the early twentieth century, physicians and scientists operating in both the clinic and the laboratory
uncovered important information regarding the neurotransmitters and neural pathways implicated in PD, the
chemical make-up and mechanism of action of traditional preparations, and treatment approaches based on
compounds for which pharmaceutical companies subsequently obtained patents.
The isolation of L-DOPA, its subsequent synthesis in the laboratory, and its formulation as a treatment for
Parkinson’s motor symptomatology are considered landmarks in the history of neurology. L-DOPA is pro-
duced in the body from the amino acid L-tyrosine by the enzyme tyrosine hydroxylase. The neurotransmitter
dopamine is formed via the decarboxylation of L-DOPA. Dopamine is critical to motor, cognitive, and emo-
tional brain functions. This has become apparent through decades of basic science, clinical, and neuroimaging
research on PD.
D, L-DOPA (the form containing left and right-handed enantiomers) was first synthesized in 1911 by Polish
chemist Kazimierz (Casimir) Funk (1884–1967). Interestingly, Funk is best known for his discovery of vita-
mins. In 1913, Marcus Guggenheim (1885–1970), a Swiss-German chemist working for Hoffmann-LaRoche in
Basel, Switzerland, isolated the pure enantiomer (mirror image molecule) L-Dopa from the legume Vicia faba
[28]. L-DOPA is the biologically active form and the form subsequently synthesized for use in treating PD. In
1937, Damodaran and Ramaswamy[25] isolated L-DOPA from Mucuna pruriens. The seeds of this plant contain
greater amounts than Vicia faba and are the source used in Ayurvedic treatments of kampavata.
7
Blonder DE GRUYTER
In 1938, more than two decades after the isolation of L-DOPA by Marcus Guggenheim, Peter Holtz dis-
covered the enzyme DOPA decarboxylase which converts L-DOPA to the biologically active amine dopamine,
which at that time was referred to as 3-hydroxytyramine[44]. In 1952 Sir Henry Dale, Nobel Laureate and British
pharmacologist, renamed 3-hydroxytyramine dopamine to better signify its relationship to L-DOPA [45]. How-
ever, it was not until the seminal paper of Kathleen Montagu, published in “Nature” in 1957, that dopamine
was known to exist in the brain [46]. Other scientists who conducted important studies of dopamine in the
1950s include Wilhelm Raab [47], Hans Weil-Malherbe [48], Peter Holtz [49], Åke Bertler and Evald Rosen-
gren [50], Oleh Hornykiewicz [51], and Isamu Sano [52]. Among the many researchers active in this field in
the 1950s, the experimental findings of Arvid Carlsson (1923-), Swedish physician and neurophysiologist, have
been recognized as ground-breaking (see Figure 4).
Figure 4: Arvid Carlsson (1923- ) giving a lecture at the 2011 Göteborg Science Festival; Source Wikipedia; Creative Com-
mons.
Licensed under Creative Commons Share-Alike 3.0 Unported license.
Carlsson was the first to demonstrate that dopamine functions as a neurotransmitter in the brain. Prior to
his work, dopamine was thought to have limited physiological activity and its major role as a precursor to
norepinephrine. Carlsson and his collaborators showed that L-DOPA, a dopamine precursor capable of cross-
ing the blood-brain barrier, has the ability to reverse symptoms induced by reserpine, a drug that depletes
norepinephrine and dopamine in the brain, lowers blood pressure, and can produce Parkinson-like symptoms
in laboratory animals [53, 54]. Dopamine does not cross the blood brain barrier and hence the precursor must
be used in targeting the brain. Carlsson’s extensive research on L-DOPA and dopamine lead him to speculate
that dopamine depletion lead to PD and that treatment with L-DOPA would restore dopamine and alleviate
symptoms [54, 55]. At first Carlsson’s findings were met with skepticism, but Carlsson observed that by 1965
a “paradigm shift” had occurred, with major researchers in the field acknowledging the important role of cat-
echolamines (epinephrine, norepinephrine, and dopamine) in the peripheral and central nervous systems [55,
56]. In 2000, Carlsson was awarded the Nobel Prize in Physiology or Medicine for his pioneering work.
Carlsson’s contemporaries, particularly Japanese neurologist Isamu Sano (1924–1975), Polish physician and
research scientist Oleh Hornykiewicz (1926-), Canadian neurologist André Barbeau (1931–1986), and Greek
American neurologist George Cotzias (1918–1977) made ground-breaking discoveries on the neuropharmacol-
ogy and clinical significance of L-DOPA and dopamine. In 1959, Isamu Sano presented a paper at the Inter-
national Catecholamine Symposium on the distribution of dopamine in the human brain [52]. One year later,
Sano gave a lecture in Tokyo describing a study he conducted in which he found decreased levels of dopamine
in the brain of a deceased Parkinson patient. That same year, Sano showed a reduction of rigidity in a Parkin-
son patient who received intravenous DL-DOPA [55, 57]. Sano’s work was originally published in Japanese
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and was not widely known at the time. Moreover, he himself expressed skepticism that the results had thera-
peutic implications. Years later, in 2000, his studies were translated into English and published in the journal
“Parkinsonism and Related Disorder” [58].
Also in 1959, Carlsson’s doctoral students Åke Bertler and Evald Rosengren [50] found dopamine localized
in the basal ganglia of the dog. This inspired Hornykiewicz and his postdoctoral fellow Herbert Ehringer to
measure dopamine in the brains of 6 Parkinson patients, 17 neurologically healthy adult controls, and 8 ad-
ditional individuals with neurodegenerative diseases involving the basal ganglia [39]. Findings indicated that
only the Parkinson patients had severe loss of dopamine in the caudate and putamen. Following confirma-
tion that PD was associated with depletion of dopamine in the basal ganglia, Hornykiewicz teamed up with
Walter Birkmayer (1910–1996), an Austrian neurologist who directed the neurological ward at “The Home for
the Aged” in Vienna. Birkmayer had access to many patients and together he and Hornykiewicz conducted
the first trial of L-DOPA, administering it intravenously to advanced Parkinson patients. Patients who were
formerly bed-ridden were able to walk across the room, run, and jump and their speech became audible and
clearly articulated [59]. The results were hailed as miraculous and eventually resulted in the development of
levodopa as a universal treatment for PD. Around the same time (1961), André Barbeau and colleagues pub-
lished a study showing reduced urinary excretion of dopamine in Parkinson patients compared to controls [60].
Subsequently, Barbeau, Theodore Sourkes, and Gerald Murray administered oral L-Dopa to PD patients and
observed transient improvement in motor function [61]. In 1963, Hornykiewicz found reductions of dopamine
in the substantia nigra in PD brains, leading him to speculate that the loss of dopamine in the basal ganglia
might be due to nigral deficiencies [62].
Throughout the 1960s, several notable neuroscientists disputed the importance of Hornykiewicz’ findings
and expressed skepticism that L-DOPA would serve as a viable therapeutic agent in the treatment of PD [63].
This changed dramatically in subsequent years. In fact, the contributions of Hornykiewicz were eventually
considered of such significance that more than 250 neuroscientists from around the world published an open
letter to the Nobel Prize in Medicine committee in the April 2001 issue of “Parkinsonism and Related Disorders”,
stating that Hornykiewicz should have been included among the Year 2000 Nobel Prize recipients- the year that
Arvid Carlsson, Paul Greengard, and Eric Kandel shared the Nobel Prize in Medicine or Physiology for their
work in signal transduction in the nervous system. The Nobel Foundation does not reverse or alter decisions-
hence Hornykiewicz did not obtained this recognition. However, he has received numerous other prestigious
scientific awards including the Wolf Prize in Medicine (1979) and the Warren Alpert Foundation Prize (2014;
Figure 5).
Figure 5: Georg Hertting, Hans Klupp, Oleh Hornykiewicz und Walter Kobinger; Source: Wikimedia Commons.
Fotoarchiv Benutzer:Coranton; Author Renate Heldt. Public Domain.
One important impediment to the use of L-DOPA as a treatment for PD was that, administered intravenously
in low doses, it was short-acting and therefore impractical. Moreover, prior studies including a self-test by
Guggenheim in 1913 demonstrated intolerable side effects such as nausea and vomiting [45]. The future of L-
DOPA as a treatment for PD looked bleak, until the late 1960s when George Cotzias published a seminal paper
in the “New England Journal of Medicine” that revolutionized the treatment of PD [64, 65]. George Cotzias was
born in Crete to prominent parents and emigrated to the United States in 1941 when German troops invaded
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Athens. He eventually graduated from Harvard Medical School and completed his residency in Neurology
at Massachusetts General Hospital. While working at Brookhaven National Laboratory on Long Island, New
York, Cotzias and his colleagues developed an oral treatment method that slowly increased the dose of L-DOPA
over a period of weeks to much higher amounts than had been previously given. Cotzias was able to do this
in part because he had access to an inpatient facility and was able to monitor and administer L-DOPA in a
very gradual and systematic manner [45]. His original intent was to restore neuromelanin concentrations in
the brain by administering L-DOPA, a melanin precursor [64]. Although he was not successful in this, he did
find that progressively increasing the dose and consistently maintaining a high dose (4–18 grams per day)
eliminated nausea and vomiting and achieved remission of Parkinson’s symptoms [65]. Cotzias also found
that co-administration of L-DOPA and a peripheral dopa decarboxylase inhibitor permitted lower therapeutic
doses of L-DOPA to be given since more drugs crossed the blood-brain barrier to be converted to dopamine in
the brain. This eradicated side effects in some patients. The combination of carbidopa, a dopa decarboxylase
inhibitor in the periphery, and levodopa is still in use today. Cotzias’ later work also lead to the development
of dopamine agonists as a treatment for PD [56]. Cotzias contributed immensely to the treatment of PD and
was referred to by collaborator Lily Tang as the “Zorba of Science” [66] . His papers were published in the
most prestigious journals and he received a number of awards, including the Albert Lasker Award for Clinical
Medical Research (Figure 6).
Figure 6: George Cotzias (1918–1977); Source: U.S. National Library of Medicine Digital Collections.
Public Domain.
Unfortunately, Cotzias developed lung cancer and died in 1977 at the age of 58 at Memorial Sloan Kettering
hospital, his then place of employment. Prominent members of the local and international communities at-
tended his memorial service, including Laurence S. Rockefeller, the North American Arch Bishop of the Greek
Orthodox Church, and several Greek ambassadors. In recognition of his accomplishments, the Greek govern-
ment issued a commemorative stamp [56].
Cotzias’ studies were open label, meaning that patients and clinicians alike knew what treatment was being
given. In 1969, Melvin Yahr (1917–2004) and colleagues conducted a prospective, double-blind, placebo con-
trolled clinical trial [67]. Yahr was born in New York City and attended New York University, earning both his
bachelor’s and medical degrees there. He received his neurology training at Montefiore Hospital in the Bronx
and later joined the faculty at the Neurological Institute of Columbia University. He was the first scientific
director of Columbia’s Parkinson’s Disease Foundation, supported by philanthropic donations (Figure 7).
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Figure 7: Melvin Yahr (1917–2004).
This photograph originally appeared in the In Memoriam essay by C. Warren Olanow published in Neurology on June
8th, 2004 [volume 62(11):1932–1933]. Reproduced with permission from Wolters Kluwer Health, Inc.
Yahr was familiar with the work of Carllson, Hornykiewicz, and Cotzias and sought additional confirma-
tion of the efficacy of L-DOPA in treating the motor symptoms of PD. Of the 60 Parkinson patients enrolled
in the 1969 study, 81% showed clinical improvement in motor symptomatology, including tremor, rigidity,
and bradykinesia. Chronic treatment was associated with dyskinesias and this problem persists to this day,
although side effects such as nausea and vomiting have been eliminated using dopa decarboxylase inhibitors
[56]. Following the study by Yahr et al, the use of L-DOPA as a treatment for PD was widely adopted and med-
ications that contained L-DOPA plus a dopa decarboxylase inhibitor received FDA approval. The most widely
used of these is marketed under the name of Sinemet®.
Melvin Yahr is perhaps best recognized for his work with his clinical fellow, Margaret Hoehn (1930–2005;
Figure 8).
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Figure 8: Margaret Hoehn (1930–2005).
Reproduced with permission from the Denver Post.
Hoehn and Yahr published the widely known “Hoehn and Yahr scale” in 1967, the same year that Cotzias
published his first important study of L-DOPA in the treatment of PD. Margaret Hoehn received her Bachelor’s
and medical degrees from the University of Saskatchewan. After training in Neurology in Vancouver, Boston,
and London she joined Melvin Yahr’s Movement Disorder Group at Columbia University as a Clinical Fellow.
In their now classic paper, Hoehn and Yahr recorded data on 802 Parkinson patients seen at the Vanderbilt
Clinic of the Columbia-Presbyterian Medical Center University between 1949 and 1964 [68]. Of these, 672 pa-
tients were determined to have idiopathic PD. During the period from 1963 to 1964, 263 Parkinson patients were
examined in the Neurology Clinic, and these examinations provided more detailed data. Hoehn and Yahr re-
ported demographic information, age of onset, clinical presentation, duration of illness, clinical progression,
and mortality rate [69]. The scale they developed lists detailed criteria to classify disease progression into five
stages. It provides precise staging criteria and was subsequently modified to include stages 1.5 and 2.5. The
modified Hoehn and Yahr scale is universally used to this day to stage Parkinson patients.
The scientific and clinical discoveries that occurred during the 1950s and 1960s rapidly altered the treatment
of PD. At the same time that Cotzias and others were experimenting with L-DOPA as a treatment for the motor
symptoms of PD, Hoehn and Yahr published their PD rating scale that would later be used in clinics world-
wide and by thousands of researchers. By the late 1960s, Cotzias’ treatment had inspired scientists at Roche
and Merck to develop and patent formulas based on the combination of L-DOPA and a dopa decarboxylase
inhibitor. Victor Lotti at Merck was involved in the development of carbidopa, the peripheral dopa decarboxy-
lase inhibitor used in Sinemet® (Latin: sin èmetos, without emesis or vomiting), which was approved in May
of 1975. Sinemet® contains L-DOPA, which crosses the blood brain barrier and is converted to dopamine by
the enzyme DOPA decarboxylase, activating D2 receptors. Carbidopa does not cross the blood brain barrier.
Instead, it inhibits DOPA decarboxylase in peripheral tissue, thus preventing L-DOPA side effects of nausea
and vomiting. Moreover, the addition of carbidopa increases the half-life of L-DOPA as well as the amount of
L-DOPA that crosses the blood brain barrier, permitting a downward titration in dose. In 1991, Dupont and
Merck joined forces to release a sustained release formulation of Sinemet® (Sinemet®CR). Currently there are
multiple forms of Sinemet® on the market and there have been numerous regulatory revisions of the product
since it was first introduced in 1975. The market for Sinemet® is in the billions of US dollars with over 5 million
Parkinson patients world-wide and the numbers expecting to surge as populations expand and age. However,
based on several factors including the introduction of generics and competitive treatments, Sinemet®’s sales
have dropped in recent years. In 2010–2011 there was a world-wide shortage of Sinemet® due to changes made
by Merck in the manufacturing of the drug. In addition, patients’ reported that the new formula, once available,
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was less long-lasting and more difficult to cut in half due to lack of scoring, despite formal clinical instructions
supporting the use of half-tablets. Taken together, the shortage, as well as changes in the formulation instituted
by the new manufacturer Mylan, proved to be very distressing to patients, and the National Parkinson Founda-
tion along with additional stakeholders spoke out to advocate for better practices and a more patient-centered
approach in the future.
While there have been many advances in the treatment of PD since the discovery and introduction of lev-
odopa in the early to mid-1970s, levodopa/carbidopa therapy is considered revolutionary [45]. The discov-
ery of levodopa as a replacement therapy for a neurotransmitter involved in a neurodegenerative disease has
served as a model in drug development. While other symptomatic treatments have been introduced since the
early 1970s, most notably dopamine agonists, levodopa remains the mainstay of treatment. Recent evidence
from the ELL-DOPA trial suggests that levodopa might be also neuroprotective- and not simply a symptomatic
dopamine replacement therapy, but that will require further substantiation [70].
Conclusions
In this review I have provided a historical perspective on the events that culminated in PD as a definitive diag-
nosis in Western Medical nosology. I have also reviewed historical data on non-Western knowledge and treat-
ment of what we in the English speaking world refer to as PD. This literature shows that TCM and Ayurveda
described the symptoms of PD centuries and millennia ago. Many of the treatments that have been utilized in
these systems are plant-based medicinals that we now know, due to the scientific discoveries of the last two
centuries, replace dopamine or act to reduce anxiety or free radical damage. In addition, ancient Eastern prac-
tices such as acupuncture, tai chi, and yoga have proven useful in the amelioration of Parkinson’s symptoms.
Western medicine, with its “mechanistic” approach, offers no counterparts to these “holistic” modalities.
Although the symptoms of PD have been known for centuries, interest in paralysis agitans grew exponen-
tially following the detailed and widely read essay of James Parkinson. Charcot’s re-naming of the “shaking
palsy” after James Parkinson was perhaps the catalyst in Western neurology and neuroscience that lead to the
consolidation of James Parkinson’s observations into a definitive diagnosis- and to a subsequent burgeoning
of scientific and clinical research. Some of the contributors to our understanding of PD may not have received
credit commensurate with their accomplishments. My hope was to shine a light on these individuals and tradi-
tions. In addition to exploring the history of PD as a disease entity, my intent was to show that cultural traditions
beyond those of ancient Greece, Western Europe, and the United States, have played a role in understanding
and treating this disease. The scientific method has undoubtedly contributed a deeper understanding of the
neural, physiologic, genetic, and pharmacologic mechanisms at play in the genesis and progression of PD, but
other traditions holding different philosophical approaches, have characterized and treated this disease as well.
In reviewing the contribution of Eastern and Western traditions to the understanding and treatment of PD, it
becomes apparent that merging these approaches, rather than dichotomizing them, will yield the best results.
At present, inquiry continues as new knowledge and cross-fertilization from various disciplines and traditions
provide information to be used in treating and perhaps eventually eradicating PD; paralysis agitans; kampavata;
chanzheng.
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